Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation

Share :
Published: 12 Sep 2022
Views: 98
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Dr Melissa Johnson presents the primary analysis of the phase 3 CodeBreaK 200 trial comparing sotorasib versus docetaxel in previously treated KRAS G12C-mutated NSCLC.

In this first, randomised phase 3 trial for a KRAS G12C inhibitor, oral sotorasib demonstrated superior PFS and ORR compared to intravenous docetaxel and had a more favourable safety profile.